PharmaTher has become the exclusive distributor of Craft Health's CraftMake™ pharmaceutical 3D printing platform in North America, covering key sectors like compounding pharmacies, telehealth, hospitals, and biotech firms. This platform enables on-demand, precise personalized medicine production, supporting PharmaTher's proprietary 503A products, FDA rare disease program, and emergency medical initiatives. The agreement also opens opportunities for PharmaTher to offer CDMO, white-label, and formulation licensing services, targeting over 10,000 potential sites and recurring revenue streams. PharmaTher plans initial platform rollouts in late 2026, aiming to capitalize on the growing personalized medicine market projected to reach $1.2 trillion by 2033.
PharmaTher's new North American distribution deal for CraftMake™ pharmaceutical 3D printing platform provides context for health sector trends. For readers following the health sector, here is Pluang's market snapshot as of Oct 01, 2026 17:52 WIB: out of 100 priced health stocks, 42 rose and 46 fell. Notable movers include INO at USD 1.25 with a 2.46% gain, MRNA at USD 188.00 down 2.37%, and XRAY at USD 9.06 up 2.26%.
Lamb Weston is set to report Q3 earnings with analysts forecasting an EPS of $0.59, down from $0.74 last year, and revenue around $1.65 billion, nearly flat compared to the prior year. The company’s "Focus to Win" strategy has generated over $100 mil...
Cal-Maine Foods reported a $58.6 million net loss and a 42% drop in net sales, driven by lower conventional egg prices. An analyst downgraded the stock to Hold with a $70 price target, reflecting a modest 2.85% upside from current levels. Despite cha...
PNC Financial Services Group received mixed analyst ratings on October 1, 2026. Evercore ISI maintained an Outperform rating but lowered its price target to $265 from $285, citing strong net interest income growth but caution on expenses and asset qu...
Accenture reported fiscal Q4 2026 earnings that exceeded analyst expectations with EPS of $3.29, up 46% year-over-year, and revenue of $18.68 billion, a 6% increase. The company also saw a 4% rise in new bookings to $22.17 billion, reflecting strong ...
Analysts have downgraded PepsiCo and lowered its price targets due to weak stock performance and sales challenges in its Frito-Lay North America segment. Despite efforts to improve products, sales remain sluggish, raising concerns about PepsiCo's ope...
